Isis Licenses Antisense Tools to Merck

genomeweb
360dx

Isis Licenses Antisense Tools to Merck

Feb 21, 2002

NEW YORK, Feb. 21 - Isis Pharmaceuticals has struck a deal with Merck to provide the pharmaceutical giant with antisense tools for drug-target validation, the company said on Thursday.

To read the full story....

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

Geisinger Exome Study IDs Breast Cancer Risk Variants That May Not Have Been Detected in Routine Care
Genetic Study Identifies Five Forms of Type 2 Diabetes
In Brief This Week: Agilent, Bionano Genomics, Opko Health, and More
People in the News: Joseph Jimenez, Marco Casarin, Steven Riedmuller, More
Biocept Plans to Sell $2.5M in Stock, Warrants
Highly Efficient Genome Editing Method Reveals Fitness of Genetic Variants in Yeast

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Main menu